Maternal serum placental growth factor at 11-13 weeks' gestation and fetal cardiac defects

被引:42
|
作者
Llurba, E. [1 ,2 ,3 ,4 ]
Syngelaki, A. [5 ,6 ]
Sanchez, O. [3 ,4 ]
Carreras, E. [1 ,2 ]
Cabero, L. [1 ,2 ]
Nicolaides, K. H. [5 ,6 ]
机构
[1] Univ Autonoma Barcelona, Maternal Fetal Med Unit, Dept Obstet, Vall dHebron Univ Hosp, Barcelona 08035, Spain
[2] Inst Salud Carlos III, Maternal & Child Hlth & Dev Network SAMID RD 08 0, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Biochem & Mol Biol Res Ctr Nanomed, Barcelona, Spain
[4] Inst Salud Carlos III, Maternal & Child Hlth & Dev Network SAMID RD 08 0, Ctr Biomed Res Rare Dis CIBERER, Barcelona, Spain
[5] Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, London, England
[6] Univ Coll London Hosp, Dept Fetal Med, London, England
关键词
cardiac defects; first-trimester screening; placental growth factor; pyramid of antenatal care; PREFRONTAL SPACE RATIO; SEPTI PELLUCIDI; TRISOMY-21; MARKERS; FETUSES; 2ND;
D O I
10.1002/uog.12346
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Objective To investigate the relationship between fetal heart defects and maternal serum placental growth factor (PIG F), a marker of placental angiogenesis. Methods Maternal serum PIGF, pregnancy-associated plasma protein-A (PAPP-A) and uterine artery pulsatility index (UtA-PI) at 11-13 weeks' gestation were compared in 68 cases of isolated fetal major heart defects and 340 normal controls. Variables were converted into multiples of the median (MoM) after adjustment for gestational age, maternal age, racial origin, weight, parity and method of conception, and then compared between groups. The cardiac defects included 11 cases of obstruction of the left ventricular outflow tract (LVOT), 25 conotruncal abnormalities and 32 valve defects. Results The median PIGF-MoM in the heart defect group was lower than in controls (0.80 (interquartile range (IQR), 0.57-1.08) vs 1.00 (IQR, 0.79-1.32); P < 0.0001). Low MP levels were observed in the presence of conotruncal and valve defects but not in the presence of LVOT defects. There was no significant difference between the group with fetal heart defects and controls in PAPP-A-MoM (0.95 (IQR, 0.68-1.28) vs 1.01 (IQR, 0.70-1.39); P = 0.292) or UtA-PI-MoM (1.01 (IQR, 0.84-1.28) vs 0.99 (IQR, 0.80-1.20); P = 0.396). Conclusion In pregnancies with isolated fetal heart defects there is evidence of impaired placental angiogenesis in the absence of impaired placental perfusion and function. Copyright (C) 2012 ISUOG. Published by John Wiley & Sons Ltd.
引用
收藏
页码:169 / 174
页数:6
相关论文
共 50 条
  • [41] Maternal serum placental growth factor (PIGF) in small for gestational age pregnancy at 11+0 to 13+6 weeks of gestation
    Poon, Leona C. Y.
    Zaragoza, Edgar
    Akolekar, Ranjit
    Anagnostopoulos, Evangelos
    Nicolaides, Kypros H.
    PRENATAL DIAGNOSIS, 2008, 28 (12) : 1110 - 1115
  • [42] Maternal hemodynamics at 11-13 weeks of gestation and the risk of pre-eclampsia
    Khalil, A.
    Akolekar, R.
    Syngelaki, A.
    Elkhouley, M.
    Nicoalides, K.
    JOURNAL OF HUMAN HYPERTENSION, 2011, 25 (10) : 627 - 627
  • [43] Maternal Thyroid Function at 11-13 Weeks of Gestation and Spontaneous Preterm Delivery
    Ashoor, Ghalia
    Maiz, Nerea
    Rotas, Michael
    Jawdat, Firas
    Nicolaides, Kypros H.
    OBSTETRICS AND GYNECOLOGY, 2011, 117 (02): : 293 - 298
  • [44] Maternal hemodynamics at 11-13 weeks' gestation and risk of pre-eclampsia
    Khalil, A.
    Akolekar, R.
    Syngelaki, A.
    Elkhouli, M.
    Nicolaides, K. H.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2012, 40 (01) : 28 - 34
  • [45] Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy
    Akolekar, Ranjit
    Minekawa, Ryoko
    Veduta, Alina
    Romero, Ximena C.
    Nicolaides, Kypros H.
    PRENATAL DIAGNOSIS, 2009, 29 (08) : 753 - 760
  • [46] Maternal serum visfatin at 11–13 weeks’ gestation in preeclampsia
    A F A Ferreira
    J C Rezende
    R de Cassia C. Oliveira
    R Akolekar
    K H Nicolaides
    Journal of Human Hypertension, 2013, 27 : 261 - 264
  • [47] Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both
    Zumaeta, A. Mazer
    Wright, A.
    Syngelaki, A.
    Maritsa, V. A.
    Bardani, E.
    Nicolaides, K. H.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2020, 56 (03) : 408 - 415
  • [48] Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia
    Birdir, Cahit
    Janssen, Katharina
    Stanescu, Anca Daniela
    Enekwe, Antje
    Kasimir-Bauer, Sabine
    Gellhaus, Alexandra
    Kimmig, Rainer
    Koeninger, Angela
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2015, 292 (05) : 1033 - 1042
  • [49] Cell free fetal DNA at 11-13 weeks of gestation is not altered in complicated pregnancies
    Koukou, Zoi
    Panteris, Eleftherios
    Manolakos, Emmanouel
    Papadopoulos, Aristeidis
    Papoulidis, Ioannis
    Papadopoulou, Eleftheria
    Relakis, Konstantinos
    Sifakis, Stavros
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 950 - 950
  • [50] Learning curve in measurement of fetal frontomaxillary facial angle at 11-13 weeks of gestation
    Yang, X.
    Chen, M.
    Wang, H. F.
    Leung, T. Y.
    Borenstein, M.
    Nicolaides, K.
    Sahota, D. S.
    Lau, T. K.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2010, 35 (05) : 530 - 534